# Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations

## TL;DR

This paper reviews how combining cephalosporins with β-lactamase inhibitors can combat drug-resistant bacteria and improve treatment outcomes.

## Contribution

The paper provides a comprehensive analysis of current and novel β-lactamase inhibitor combinations for treating multidrug-resistant infections.

## Key findings

- β-lactamase inhibitor combinations like CAZ-AVI and TOL-TAZ show clinical efficacy against resistant bacteria.
- New combinations such as cefepime-enmetazobactam are being explored for XDR bacteria.
- Comparative analyses highlight the importance of pharmacokinetics and safety in optimizing these therapies.

## Abstract

This review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options. It examines β-lactam resistance mechanisms, established combinations (e.g., ticarcillin/clavulanic acid, piperacillin/tazobactam), and the clinical efficacy of newer therapies like ceftazidime/avibactam (CAZ-AVI) for carbapenem-resistant Klebsiella pneumoniae (CRKP) and ceftolozane/tazobactam (TOL-TAZ) for MDR Pseudomonas aeruginosa. Additionally, novel combinations (e.g., cefepime-enmetazobactam, cefepime-taniborbactam) are discussed for tackling extensively drug-resistant (XDR) bacteria.

Through comparative analyses, this review provides key insights into efficacy, resistance, pharmacokinetics, and safety, guiding researchers in optimizing antimicrobial strategies and clinicians in managing MDR infections, while supporting antibiotic management and future research.